Overexpression of cyclin l2 inhibits growth and enhances chemosensitivity in human gastric cancer cells

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 4, 2012, Pages 1425-1430

  Li, Hong Li ^a   Huang, Ding Zhi ^a   Deng, Ting ^a   Zhou, Li Kun ^a   Wang, Xia ^a   Bai, Ming ^a   Ba, Yi ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle; Chemosensitivity; Cyclin l2; Gastric cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; CASPASE 3; CCNL2 PROTEIN, HUMAN; CISPLATIN; CYCLINE; DOCETAXEL; FLUOROURACIL; INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN BCL 2; TAXOID; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CELL CYCLE CHECKPOINT; CELL CYCLE G0 PHASE; CELL PROLIFERATION; DOWN REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; STOMACH TUMOR; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYCLINS; DOWN-REGULATION; FLUOROURACIL; G0 PHASE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; STOMACH NEOPLASMS; TAXOIDS; TRANSCRIPTION FACTORS; TRANSFECTION; UP-REGULATION;

EID: 84873035328     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.4.1425     Document Type: Article

References (21)

1. Ajani JA, Moiseyenko VM, Tjulandin S, et al (2007). Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol, 25, 3205-9.
2. Alenzi FQ, Lotfy M, Wyse R (2010). Swords of cell death: caspase activation and regulation. Asian Pac J Cancer Prev, 11, 271-80.
3. Bang YJ, Van Cutsem E, Feyereislova A, et al (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. The Lancet, 376, 687-97.
4. Barton C, Davies D, Balkwill F, et al (2005). Involvement of both intrinsic and extrinsic pathways in IFN-gamma-induced apoptosis that are enhanced with cisplatin. Eur J Cancer, 41, 1474-86.
5. Duman-Scheel M, Weng L, Xin S, et al (2002). Hedgehog regulates cell growth and proliferation by inducing Cyclin D and Cyclin E. Nature, 417, 299-304.
6. Egloff AM, Vella LA, Finn OJ (2006). Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res, 66, 6-9.
7. Graaf K, Hekerman P, Spelte O, et al (2004). Characterization of cyclin L2, a novel cyclin with an arginine/serine-rich domain phosphorylation by DYRK1A and colocalization with splicine factors. J Biol Chem, 279, 4612-24.
8. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. Ca Cancer J Clin, 6, 69-90.
9. Lazzarini R, Moretti S, Orecchia S, et al (2008). Enhanced antitumor therapy by inhibion of p21waf1 in human malignant mesothelioma. Clin Cancer Res, 14, 5099-107.
10. Li HL, Wang TS, Li XY, et al (2007). Overexpression of cyclin L2 induces apoptosis and cell-cycle arrest in human lung cancer cells. Chin Med J, 120, 905-9.
11. Li S, Wang A, Jiang W, et al (2008). Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. BMC Cancer, 8, 103-11.
12. Loyer P, Trembley JH, Grenet JA, et al (2008). Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: influence of cyclin L isoforms on splice site selection. J Biol Chem, 283, 7721-32.
13. Mori T, Anazawa Y, Matsui K, et al (2002). Cyclin K as a direct transcriptional target of the p53 tumor suppressor. Neoplasia, 4, 268-74.
14. Ohtsu A, Shah MA, Van Cutsem E, et al (2011). Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol, 29, 3968-76.
15. Redon R, Hussenet T, Bour G, et al (2002). Amplicon mapping and transcriptional analysis pinpoint cyclin L as a candidate oncogene in head and neck cancer. Cancer Res, 62, 6211-7.
16. Reedijk J, Lohman PH (1985). Cisplatin: synthesis, antitumour activity and mechanism of action. Pharm Weekbl Sci, 7, 173-80.
17. Shapiro GI (2006). Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol, 24, 1770-83.
18. Swanton C, Marani M, Pardo O, et al (2007). Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell, 11, 498-512.
19. Tabernero J, Macarulla T, Ramos FJ, et al (2005). Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol, 16, 1740-8.
20. Wagner AD, Grothe W, Haerting J, et al (2006). Chemotherapy in advanced gastric cancer: A systematic review and metaanalysis based on aggregate data. J Clin Oncol, 24, 2903-9.
21. Yang L, Li N, Wang C, et al (2004). Cyclin L2, a novel RNA polymerase II-associated cyclin, is involved in pre-mRNA splicing and induces apoptosis of human hepatocellular carcinoma cells. J Biol Chem, 279, 11639-48.